NCT07159217View on ClinicalTrials.gov

Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

August 30, 2025

Primary Completion Date

May 31, 2027

Study Completion Date

May 31, 2028

Conditions
Biliary Tract CancerDisitamab VedotinLenvatinibImmune Checkpoint Inhibitors
Interventions
DRUG

Disitamab Vedotin

2.0 mg/kg administered intravenously every three weeks

DRUG

Lenvatinib

≥60 kg: 12 mg once daily, or \<60 kg: 8 mg once daily

DRUG

Pembrolizumab

200 mg intravenously every three weeks

DRUG

Toripalimab

240 mg intravenously every three weeks

DRUG

Camrelizumab

200 mg intravenously every three weeks

Trial Locations (1)

Unknown

Chinese Academy of Medical Sciences, Peking Union Medical College Hospital, Beijing

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER